MARKET

ONTX

ONTX

Onconova
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.720
-0.390
-7.63%
After Hours: 4.680 -0.04 -0.85% 18:28 09/20 EDT
OPEN
4.900
PREV CLOSE
5.11
HIGH
5.00
LOW
4.700
VOLUME
247.73K
TURNOVER
--
52 WEEK HIGH
28.95
52 WEEK LOW
3.600
MARKET CAP
74.49M
P/E (TTM)
-2.8978
1D
5D
1M
3M
1Y
5Y
Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit
Presentation to feature data from the Phase 1/2a investigator-initiated study of rigosertib-nivolumab combination in KRAS mutated non-small cell lung cancerNEWTOWN, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clini...
GlobeNewswire · 12h ago
Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
NEWTOWN, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be ...
GlobeNewswire · 09/09 12:00
Onconova Therapeutics to Launch At-the-Market Offering of $25 Million Common Shares
MT Newswires · 08/23 06:00
BRIEF-Onconova Therapeutics Reports Second Quarter 2021 Financial Results
reuters.com · 08/12 21:53
Recap: Onconova Therapeutics Q2 Earnings
Shares of Onconova Therapeutics (NASDAQ:ONTX) moved higher by 2.1% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 575.00% over the past year to ($0.27), which beat the estimate of ($0.28).
Benzinga · 08/12 21:25
Onconova Therapeutics Q2 EPS $(0.27) Beats $(0.28) Estimate, Sales $57.00K Beat $20.00K Estimate
Onconova Therapeutics (NASDAQ:ONTX) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.28) by 3.57 percent. This is a 575 percent decrease over losses of $(0.04) per share
Benzinga · 08/12 21:13
-- Earnings Flash (ONTX) ONCONOVA THERAPEUTICS Posts Q2 Revenue $57,000, vs. Street Est of $0.02M
MT Newswires · 08/12 16:25
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONTX. Analyze the recent business situations of Onconova through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONTX stock price target is 20.00 with a high estimate of 29.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 2.96M
% Owned: 18.74%
Shares Outstanding: 15.78M
TypeInstitutionsShares
Increased
9
249.70K
New
7
160.89K
Decreased
9
125.13K
Sold Out
40
927.59K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Director
James Marino
President/Chief Executive Officer/Director
Steven Fruchtman
Chief Financial Officer
Mark Guerin
Vice President/General Counsel
Abraham Oler
Other
Mark Gelder
Director
Henry Bienen
Director
Jerome Groopman
Director
Viren Mehta
Director
Terri Shoemaker
Director
Jack Stover
Director
Anne Vanlent
No Data
  • All
  • Financials
  • Insiders
More
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONTX stock methods without spending real money on the virtual paper trading platform.